Tag

China Archives | Page 85 of 199 | Smartkarma

Daily Brief China: Shaanxi Coal Industry, iRay Technology and more

By | China, Daily Briefs

In today’s briefing:

  • Quiddity Primer for SSE 50/180/380 Index Rebalance Events
  • China Healthcare Weekly (Aug.4) – TCM Rally Ends, P/E Ratio Becomes Ineffective, IRay Technology


Quiddity Primer for SSE 50/180/380 Index Rebalance Events

By Janaghan Jeyakumar, CFA

  • SSE 50 and SSE180, respectively, aim to represent the performance of the 50 and 180 largest and most liquid A-share stocks listed on Shanghai Stock Exchange. 
  • SSE 380 consists of 380 mid-cap stocks which are selected from the remaining Shanghai listed A-shares after the constituents of SSE 180 Index. 
  • In this insight, we take a brief look at the index selection methodology and the historical price and volume performance of the SSE 50/180/380 index rebalance baskets.

China Healthcare Weekly (Aug.4) – TCM Rally Ends, P/E Ratio Becomes Ineffective, IRay Technology

By Xinyao (Criss) Wang

  • The rally of TCM companies has probably come to an end. But we think there would be good trading opportunities in 23Q4. Things could become challenging again in 24Q1.
  • If P/E is used when calculating the valuation of innovative pharmaceutical companies, unreasonable situations may arise. Sales profit rather than net profit could be a better choice for P/E.
  • Although iRay’s current P/E has fallen in reasonable range, due to concerns about its long-term growth prospects, valuation could further decline in long term. So, just short-term trade is recommended.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: PCCW Ltd, Taste Gourmet, Toyota Motor, MGM China Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • PCCW’s Stub Ops Spill More Red Ink
  • Taste Gourmet (8371 HK)
  • Toyota to Ramp Up Electric Car Push in China With R&D Revamp
  • Weekly Wrap – 04 Aug 2023


PCCW’s Stub Ops Spill More Red Ink

By David Blennerhassett

  • Net of HKT Ltd (6823 HK), PCCW Ltd (8 HK) recorded negative EBITDA of HK$378mn in the 1H23.
  • This is the largest six-month negative EBITDA figure since the EBITDA loss of HK$427mn in 2H22, and the third largest in the past decade. 
  • PCCWs current discount to NAV is at an unsustainable 5%.

Taste Gourmet (8371 HK)

By Oriental Value

  • With that out of the way, let’s dive into Taste Gourmet, a catering group listed in the secondary market (or GEM board) of the Hong Kong Stock Exchange.
  • Catering is usually a business with little moat, characterised by low barriers to entry. 
  • While some brands are widely recognizable, humans generally want to devour something different each day, therefore it is an everyday struggle for restaurants to stand out among competition.

Toyota to Ramp Up Electric Car Push in China With R&D Revamp

By Caixin Global

  • Toyota Motor Corp., the world’s biggest car seller, has announced plans to consolidate its research and development (R&D) resources in China and ramp up its focus on electric vehicles (EVs), as it attempts to revive stalling sales in the highly competitive market.
  • The Japanese automaker said on Monday it would change the name of its largest R&D facility in China from Toyota Motor Engineering & Manufacturing (China) Co. Ltd. to Intelligent ElectroMobility R&D Center by TOYOTA (China) Co. Ltd., and consolidate engineers from its three China ventures into the newly named facility based in Changshu, Jiangsu province.
  • Among other plans, it would also strengthen local development of electrified vehicles (EVs) including battery, hybrid and plug-in hybrid models and accelerate the development of an electric powertrain with its two biggest suppliers, Denso Corp. and Aisin Corp., the company said.

Weekly Wrap – 04 Aug 2023

By Charles Macgregor

Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.

In this Insight:

  1. Country Garden Holdings Co
  2. Vedanta Resources
  3. China Jinmao Holdings
  4. Geely Auto
  5. First Pacific Co

and more…


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: S.F. Holding, AAC Technologies Holdings, China Cinda Asset Management, MGM China Holdings and more

By | China, Daily Briefs

In today’s briefing:

  • SF Holding (002352 CH): H-Share Listing & Index Implications
  • Asia HY Monthly – July 2023 – Lucror Analytics
  • China Cinda to Sell $166 Million of Founder Securities Shares
  • Morning Views Asia: Country Garden Holdings Co, MGM China Holdings, Vedanta Resources


SF Holding (002352 CH): H-Share Listing & Index Implications

By Brian Freitas

  • S.F. Holding (002352 CH) could raise between HK$26-33bn (US$3.4-4.2bn) in its H-share listing depending on the H-shares discount and exercise of the overallotment option.
  • The H-shares could get Fast Entry to certain indices and regular entry to others depending on the number of shares that are allotted to cornerstone and/or strategic investors.
  • The H-shares will be added to Southbound Stock Connect following the end of the price stabilisation period. Inclusion in the Hang Seng Composite Index will come later.

Asia HY Monthly – July 2023 – Lucror Analytics

By Charles Macgregor

The Asia Monthly focuses on providing updates on recent events, information on new issues and spread movements, as well as summarising our top picks. The Asia Monthly is intended to broaden investors’ understanding of the Asian USD high-yield market.


China Cinda to Sell $166 Million of Founder Securities Shares

By Caixin Global

Founder Securities Co. Ltd.’s third-largest shareholder, China Cinda Asset Management Co. Ltd., is selling 2% of the brokerage’s stock worth 1.2 billion yuan ($166 million).

The share sale is to meet Cinda’s needs for corporate operations, Founder Securities said Monday night in a statement.

China Cinda, the nation’s biggest state-owned bad-debt manager, plans to sell as many as 165 million shares of Founder Securities between Aug. 23 and Feb. 22, 2024, through centralized bidding, the brokerage said.


Morning Views Asia: Country Garden Holdings Co, MGM China Holdings, Vedanta Resources

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Flat Glass, Times Neighborhood, Luckin Coffee, Hua Hong Semiconductor, WuXi AppTec, Taste Gourmet, Immuno Cure BioTech and more

By | China, Daily Briefs

In today’s briefing:

  • Hong Kong CEO & Director Dealings (2 August): Flat Glass, Arts Optical, Sky Light Holdings
  • Country Garden Services (6098 HK): 1H23 Profit Warning A Good Read-Across For The Sector
  • [Luckin Coffee (LKNCY US, BUY, TP US$43) TP Change]: Economies of Scale Brings Margin Improvement
  • [Hua Hong (1347 HK, BUY, TP HK$34) TP Change]: Valuation Is Attractive Post-Shanghai Listing
  • WuXi AppTec (2359.HK/603259.CH) 23H1 – Is It Time to Start Being Optimistic?
  • Taste Gourmet: Q1 FY24 Preview, Another Strong Quarter in the Making
  • Immuno Cure Bags US$12M Series A Funding, Gears up for Hong Kong IPO


Hong Kong CEO & Director Dealings (2 August): Flat Glass, Arts Optical, Sky Light Holdings

By David Blennerhassett

  • The data in this insight is collated from the “shareholding disclosure” link on the HKEx website
  • Often there is a corresponding HKEx announcement on the increase – or decrease – in the shareholding by directors. Or pledging. However, such disclosures are by no means an absolute.
  • Stocks mentioned in this regular insight include Flat Glass (6865 HK), Arts Optical Intl Hldgs (1120 HK), and Sky Light Holdings Ltd (3882 HK).

Country Garden Services (6098 HK): 1H23 Profit Warning A Good Read-Across For The Sector

By Steve Zhou, CFA

  • Country Garden Services (6098 HK) announced a profit warning for 1H23 last night, expecting sales to increase by 3-4% yoy and net profit to see a 0-10% drop yoy.
  • The company also announced the intention to repurchase up to 10% of total shares outstanding. 
  • Share price up +18% following the profit warning and share buyback announcement – a good read-across for the rest of the sector that will report interim results later this month. 

[Luckin Coffee (LKNCY US, BUY, TP US$43) TP Change]: Economies of Scale Brings Margin Improvement

By Shawn Yang

  • Luckin Coffee reported 2Q23 revenue beat our est. by 7.5%, and non-GAAP NI beat our estimate by 84.1%. 
  • The top-line beat is driven by stronger product sold on average store sales, the bottom-line beat is driven by economies of scale and less than estimated sales promotion.  
  • We maintain the stock as BUY rating and raise TP by US$5.5 to US$43/ADS (27x PE in 2023) to factor in the outlook of sustainable margin improvement.

[Hua Hong (1347 HK, BUY, TP HK$34) TP Change]: Valuation Is Attractive Post-Shanghai Listing

By Shawn Yang

  • We expect Hua Hong to report C1Q23 top-line and non-IFRS net income in-line and (24%) vs. cons., respectively, missing mainly due to one-time costs. 
  • Hua Hong’s post-A share IPO valuation is cheap at 0.7x P/B, but we expect that weakening industrials demand and a slow recovery to hamper shipments.
  • We maintain BUY but cut Hua Hong’s TP to HK$ 34 reflecting lowered wafer shipments estimates for FY24/25. Our TP implies 15x FY24 PE.

WuXi AppTec (2359.HK/603259.CH) 23H1 – Is It Time to Start Being Optimistic?

By Xinyao (Criss) Wang

  • The market’s reaction to WuXi AppTec’s 23H1 report was positive due to some improvements in performance, but we don’t think WuXi AppTec has reversed its predicament completely if look closely.
  • We deep dive the challenges/risks in macro environment faced by US/Europe. The orders WuXi AppTec received from MNCs can’t guarantee future growth momentum if the US cannot achieve “soft landing”.
  • We advise investors not to be blinded by the high growth of CXO in the past since the prosperity of CXO industry may face continuous downward pressure in the future.

Taste Gourmet: Q1 FY24 Preview, Another Strong Quarter in the Making

By Sameer Taneja

  • We estimate Taste Gourmet (8371 HK) to deliver 39% YoY revenue growth and about 13% YoY profit growth (adj 350% YoY) for Q1 FY24e, to be declared on August 10th.
  • The company is expected to go ex-dividend on the 4th of August and pay out a 5.2-HK cent final dividend by the 24th of August for FY23.  
  • Trading at 6x FY24e PE /20% of the market capitalization in cash and a 9-10% dividend yield ( based on a 50-60% payout ratio) represents a great investment opportunity.

Immuno Cure Bags US$12M Series A Funding, Gears up for Hong Kong IPO

By e27

  • Hong Kong-based Immuno Cure BioTech has closed the US$12 million tranche of its US$27 million Series A fundraising round, led by Gobi Partners-managed AEF Greater Bay Area Fund.
  • The biotech company will use the capital to accelerate the development of DNA vaccines and antibodies besides preparing for an IPO in Hong Kong.
  • Immuno Cure focuses on R&D of immunotherapies for cancers, inflammatory and infectious diseases based on its patented “PD-1-enhanced DNA Vaccine Platform” and “Anti-Δ42PD1 Antibody Platform” with two DNA vaccine candidates, ICVAX and ICCOV, currently in clinical trials.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: NARI Technology Co Ltd A, Haidilao International Holding, CK Asset Holdings, Water Oasis, Yuexiu Property , China Traditional Chinese Medicine and more

By | China, Daily Briefs

In today’s briefing:

  • Offshore China ETFs Rebalance Preview: Two Changes in September
  • China Catering Sector: Positioning for Interim Results
  • CKA (1113 HK): A Strong Conglo, Focus on Capital Mgmt & Consistently Create Value for Shareholders
  • Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2023
  • Yuexiu Property – Tear Sheet – Lucror Analytics
  • China Traditional Chinese Medicine (570.HK) 23H1-Positive Profit Alert Reinforce Optimism About 2023


Offshore China ETFs Rebalance Preview: Two Changes in September

By Brian Freitas


China Catering Sector: Positioning for Interim Results

By Eric Chen

  • Positive profit alerts from both Jiumaojiu and Haidilao reflect strong gain in operating efficiency but also point to looming growth deceleration as brands mature.
  • We see valuation more reasonable due to a combination of sector de-rating in 1H23 and higher visibility into earnings recovery post these profit alerts.
  • Yum China remains best long-term play in China catering sector in our view. While both Haidilao and Xiabuxiabu present trading opportunity, we are still cautious about Jiumaojiu.

CKA (1113 HK): A Strong Conglo, Focus on Capital Mgmt & Consistently Create Value for Shareholders

By Jacob Cheng

  • CKA is a well diversified conglomerate with residential DP and IP (office and retail) in HK and China, with sizable business in UK (pubs) and infra assets in EU
  • CKA focuses on capital mgmt (share buybacks, M&As, disposals), and consistently unlock value for shareholders.  CKA is in net cash, its strongest balance sheet position for 20 years
  • Valuation is extremely compelling. We recommend CKA as a long-term buy and hold for investors and traders

Shortlist Of High Conviction Ideas: Income, Value, and Margin of Safety – August 2023

By Sameer Taneja


Yuexiu Property – Tear Sheet – Lucror Analytics

By Charles Macgregor

We view Yuexiu Property (YXP) as “Low Risk” on the LARA scale. Our assessment takes into account the company’s: [1] parental support from Guangzhou Yuexiu (GYX), which is an SOE; [2] sound operating track record; [3] good contracted sales performance; and [4] geographical diversity, with a focus on the Greater Bay Area. These are balanced against weak market sentiment and a change in government policy.

Our fundamental Credit Bias on YXP is “Stable”. We expect its near-term credit profile to be supported by stable sales and cash collection, with Transit-oriented Development being a key factor underpinning the company’s growth. While YXP likely has limited room for margin improvement given the industry trends, we believe YXP could still outperform most of its competitors in terms of profitability. In addition, we expect the developer to have good funding access, given parent GYX’s SOE status and close relationship with the municipal government.

Controversies are “Immaterial” and the ESG Impact on Credit is “Neutral”.

We maintain our “Buy” recommendation on the YUEXIU curve. We like the company’s fundamentals and its support from GYX. We also expect YXP’s near-term credit profile to be supported by stable sales and cash collection.


China Traditional Chinese Medicine (570.HK) 23H1-Positive Profit Alert Reinforce Optimism About 2023

By Xinyao (Criss) Wang

  • The rebound of China TCM’s performance in 23H1 could be mainly driven by its core concentrated TCM granules business as well as the recovery of other businesses after China reopens. 
  • We analyzed the potential performance changes that may occur in 23H2. The full year performance of 2023 will be worth looking forward to. We expect the share price to rebound.
  • TCM VBP is always an issue. Due to the high base in 2023, the YoY performance growth in 2024 could decline, which may put pressure on valuation at that time. 

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Oriental Watch, Semiconductor Manufacturing International Corp (SMIC), Sino-Ocean Group and more

By | China, Daily Briefs

In today’s briefing:

  • Oriental Watch (398 HK): Strong Data Points for H1 FY24, 14% Yield + >50% Mkt Cap in Cash
  • [SMIC (0981 HK, BUY, TP HK$26) Target Price Change]: Pricing Power Courtesy of Export Restrictions
  • Morning Views Asia: Country Garden Holdings Co, Pan Brothers, Pertamina Geothermal Energy PT


Oriental Watch (398 HK): Strong Data Points for H1 FY24, 14% Yield + >50% Mkt Cap in Cash

By Sameer Taneja

  • Oriental Watch (398 HK) cycled into favorable comps for April-June 2023 owing to COVID-related closures in China in 2022 for the same period. 
  • Another favorable data point was the Emperor Watch & Jewellery (887 HK) positive profit alert for H1 FY23 ( Jan-Jun 2023), where the company guided >100% net profit growth. 
  • Oriental Watch (398 HK) trades at 6.9x FY24e, with more than 50% of the market cap in cash and a ~100% payout ratio resulting in a 14% dividend yield. 

[SMIC (0981 HK, BUY, TP HK$26) Target Price Change]: Pricing Power Courtesy of Export Restrictions

By Shawn Yang

  • We expect SMIC to report C1Q23 top-line and non-IFRS net income 2% and 16% vs. consensus, respectively.
  • We suggest SMIC’s ability to supply sanctioned firms with 14/7nm nodes provides it with significant pricing power. We expect the decline in SMIC’s wafer ASP to slow.
  • We expect overall 2H demand to improve due to (1) normalizing fabless inventory levels, and (2) stabilized smartphone demand. We maintain BUY rating and raise our TP to HK$ 26.

Morning Views Asia: Country Garden Holdings Co, Pan Brothers, Pertamina Geothermal Energy PT

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Piotech , Prosus NV, L’Occitane, Dali Foods Group, China Power International, Unisound AI Technology, Nayuki Holdings, Greenland Holdings Corp, Trip.com and more

By | China, Daily Briefs

In today’s briefing:

  • STAR50 Index Rebalance Preview: Potential Changes Playing Catchup
  • Prosus: The More Things Change…
  • Weekly Deals Digest (30 Jul) – L’Occitane, Dali, Eoflow, Toshiba, Pacific Current, Estia
  • Dali Foods (3799 HK): 23 August Scheme Meeting. IFA Says Fair
  • China Power International (2380 HK): A Major Move to Raise Clean Energy Exposure
  • Unisound AI Technology IPO Valuation Analysis: SaaS Valuation Multiples Appear Rich For The Stock
  • [Nayuki (2150 HK, BUY, TP HK$9.3) TP Change]: Store Operating Profit Margin Improvement On-Track
  • Morning Views Asia: China Hongqiao, Greenland Holdings Corp, Lippo Karawaci
  • Monthly Chinese Tourism Tracker | Outbound: Mixed Signals | Domestic: Steady | (July 2023)


STAR50 Index Rebalance Preview: Potential Changes Playing Catchup

By Brian Freitas

  • The review period for the September rebalance ends today. The changes could be announced on 25 August with the implementation taking place after the close on 8 September.
  • The upcoming launch of the STAR100 Index could result in the index committee continuing to use a 6-month minimum listing history resulting in two changes to the index.
  • One way turnover is estimated at 2.3% resulting in a one-way trade of CNY 2,658m. The impact on the deletions will be much larger than that on the inclusions.

Prosus: The More Things Change…

By Wium Malan, CFA

  • Prosus looks to continue to cut its stake in Tencent by 2-3% every year to fund its open-ended share buyback program.
  • Evidence would suggest that the buyback is set to continue at a relatively steady pace for the foreseeable future, which should support the discount to NAV going forward.
  • The simplification of the shareholding structure, to remove the cross-holding, could sustainably reduce Prosus’ discount to NAV by roughly 10%.

Weekly Deals Digest (30 Jul) – L’Occitane, Dali, Eoflow, Toshiba, Pacific Current, Estia

By Arun George


Dali Foods (3799 HK): 23 August Scheme Meeting. IFA Says Fair

By David Blennerhassett

  • Back on the 27 June, Dali Foods Group (3799 HK), announced a privatisation Offer by way of a Scheme from its founder/chairman/CEO Xu Shihui.
  • The cancellation price, which has been declared final, was HK$3.75/share, a decent 37.87% premium to undisturbed.
  • The Scheme Doc is now out. The Scheme Meeting is the 23 August. Xu and concert parties control 88.89%, therefore a blocking stake is 1.11% of shares out. 

China Power International (2380 HK): A Major Move to Raise Clean Energy Exposure

By Osbert Tang, CFA

  • The Rmb10.8bn acquisition of clean energy assets from parent by China Power International (2380 HK) is positive in raising its clean energy proportion to over 70% of total capacity.
  • The drop in share price reflects concerns about elevation of gearing and the need for potential equity funding. However, even all equity financing scenario will only dilute EPS by 1%.
  • We think its earnings quality will improve, balance sheet will be enhanced and profitability will be raised. Its 1H23 positive profit alert also showed a recovery in operational performance. 

Unisound AI Technology IPO Valuation Analysis: SaaS Valuation Multiples Appear Rich For The Stock

By Andrei Zakharov

  • Unisound AI Technology, a Beijing-based AI unicorn, filed to go public in Hong Kong. I used a diverse peer group of domestic AI companies to come up with IPO valuation. 
  • From a peer group perspective, I arrived at an IPO valuation close to ~RMB12b (or ~$1.7B), using a ~15x EV/CY22 Revenue to my 2023 revenue estimate of RMB780m (+30% y/y).
  • However, I believe SaaS valuation multiples may appear rich for the stock, keeping in mind non-recurring revenue and the high hardware cost in the total cost of sales and services.

[Nayuki (2150 HK, BUY, TP HK$9.3) TP Change]: Store Operating Profit Margin Improvement On-Track

By Shawn Yang

  • Our 1H23 revenue estimate is 8.7% lower than consensus, and we expect 1H23 NPM at breakeven vs. consensus at 5%。
  • Mainly because teahouse brands in China had suffered the intensified competition from the price war in Coffee industry.
  • We maintain the stock as BUY rating as the margin improvement process is gradual showing effect, while we lower TP by US$2 to US$9.3 to reflect the intensified competition pressure.

Morning Views Asia: China Hongqiao, Greenland Holdings Corp, Lippo Karawaci

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Monthly Chinese Tourism Tracker | Outbound: Mixed Signals | Domestic: Steady | (July 2023)

By Daniel Hellberg

  • We see decidedly mixed signals in Chinese outbound tourism numbers from June
  • Meanwhile, the modest pace of the recovery in domestic air traffic continued last month
  • What to look for in Q2/H1 earnings results over the next several weeks

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: MOG Holdings, Genscript Biotech, Dali Foods Group, Tencent and more

By | China, Daily Briefs

In today’s briefing:

  • Index Rebalance & ETF Flow Recap: LQ45/IDX30, FXI, New Deal, KOSPI, KQ150, LG Energy, IN Float, TTMT
  • China Healthcare Weekly (Jul.28) – Starting Point of New Prosperity, MNCs Change Strategy, Genscript
  • Dali Foods (3799 HK): Scheme Vote on 23 August
  • ECM Weekly (30th July 2023) – Tryt, Genda, Cinema XXI, Abacus, Robosense, Qiniu, Muthoot, LianLian


Index Rebalance & ETF Flow Recap: LQ45/IDX30, FXI, New Deal, KOSPI, KQ150, LG Energy, IN Float, TTMT

By Brian Freitas

  • The changes to the LQ45/IDX30 were announced last week and will be implemented Monday. The PSE also announced that there would be no changes for the PCOMP INDEX in August.
  • There are a bunch of review cutoffs on Monday, most notably for the Nikkei 225 (NKY INDEX), STAR50 INDEX, the NIFTY family of indices and the KRX New Deal indices.
  • There were inflows to China focused ETFs and outflows from Taiwan and Korea focused ETFs during the week.

China Healthcare Weekly (Jul.28) – Starting Point of New Prosperity, MNCs Change Strategy, Genscript

By Xinyao (Criss) Wang

  • AD (Alzheimer Disease) and RNAi are one of the most valuable breakthroughs in global pharmaceutical industry in recent years. We think they may bring the next round of biopharmaceutical prosperity.
  • MNCs have begun to adjust their strategic business model in China. Licensing cooperation and equity investments in China biotech companies are expected to become a new trend.
  • We can’t expect too much from Genscript Biotech (1548 HK) just because Legend Bio’s CAR-T product has good sales performance. Genscript could underperform based on our analysis.

Dali Foods (3799 HK): Scheme Vote on 23 August

By Arun George

  • Dali Foods Group (3799 HK)‘s scheme document is out with the court meeting scheduled for 23 August. The IFA considers the HK$3.75 per share offer to be fair and reasonable. 
  • Key condition is approval by at least 75% of disinterested shareholders (<10% of all disinterested shareholders rejection). No independent shareholder holds a blocking stake. 
  • Sector sentiment has modestly weakened. This looks done. At the last close and for the 8 September payment, the gross and annualised spread is 3.6% and 34.8%, respectively.

ECM Weekly (30th July 2023) – Tryt, Genda, Cinema XXI, Abacus, Robosense, Qiniu, Muthoot, LianLian

By Sumeet Singh

  • Aequitas Research puts out a weekly update on the deals that were covered by the team recently along with updates for upcoming IPOs.
  • In the IPO space, the coming week will see Cinema XXI listing.
  • Given that we are in the middle of earnings season, there were no new placements this week.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: Broad General Holding, Sino-Ocean Group and more

By | China, Daily Briefs

In today’s briefing:

  • Broad General Holding Pre-IPO Tearsheet
  • Weekly Wrap – 28 Jul 2023


Broad General Holding Pre-IPO Tearsheet

By Clarence Chu

  • Broad General Holding (BG HK) is looking to raise at least US$100m in its upcoming Hong Kong IPO. The bookrunners on the deal are Deutsche Bank and Everbright Securities.
  • Broad General Holding is a private investment fund manager with a focus on serving high network individuals (HNWIs).
  • As per F&S, the firm was the second largest private investment fund manager in China focused on serving HNWIs in terms of total AUM as of Dec 22.

Weekly Wrap – 28 Jul 2023

By Charles Macgregor

Lucror Analytics Weekly Wraps provide an overview of all Morning Views comments and reports published by our analyst team in the past week, and also showcase a list of the most-read reports.

In this Insight:

  1. 21Vianet Group
  2. SK Hynix
  3. Yuexiu Property
  4. Nameson Holdings
  5. China Jinmao Holdings

and more…


💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars



Daily Brief China: XPeng , Shanghai United Imaging Health, Sino-Ocean Group, AAC Technologies Holdings, Lianlian DigiTech and more

By | China, Daily Briefs

In today’s briefing:

  • [XPeng(XPEV US, BUY, TP US$24.3)TP Change]: Potential of Tech Licensing and EV Sales Lifts Valuation
  • Quiddity Leaderboard CSI 300/​500 Dec 22: Massive Baskets, US$2.5bn One-Way
  • Morning Views Asia: Sands China, Sino-Ocean Service, SK Hynix, O-Net Technologies (Group)
  • Asia HY Trade Book – July 2023 – Lucror Analytics
  • LianLian DigiTech IPO: The Bear Case


[XPeng(XPEV US, BUY, TP US$24.3)TP Change]: Potential of Tech Licensing and EV Sales Lifts Valuation

By Shawn Yang

  • VW’s long-term software dilemma caused delays of new EV model launch. Thus, leveraging established software capability of Xpeng could help VW catch up and shorten its R&D cycle.
  • We see two benefits for Xpeng: 1) a new revenue stream from tech licensing and potential reduction of supply chain costs; 2) VW’s endorsement  could help Xpeng’s overseas expansion.
  • We think the potential of Xpeng’s high-margin tech licensing being opened to more VW models and other OEMs. Our TP implies 2.5x 2024PS

Quiddity Leaderboard CSI 300/​500 Dec 22: Massive Baskets, US$2.5bn One-Way

By Janaghan Jeyakumar, CFA

  • CSI 300 represents the 300 largest stocks by market capitalization and liquidity from the entire universe of Shanghai and Shenzhen Stock Exchanges. CSI 500 represents the next largest 500 names.
  • In this insight, we take a look at the potential ADDs/DELs for the CSI 300 and CSI 500 rebalance in December 2023.
  • I currently expect 13 ADDs/DELs for CSI 300 and 50 ADDs/DELs for CSI 500. 

Morning Views Asia: Sands China, Sino-Ocean Service, SK Hynix, O-Net Technologies (Group)

By Charles Macgregor

Lucror Analytics Morning Views comprise our fundamental credit analysis, opinions and trade recommendations on high yield issuers in the region, based on key company-specific developments in the past 24 hours. Our Morning Views include a section with a brief market commentary, key market indicators and a macroeconomic and corporate event calendar.


Asia HY Trade Book – July 2023 – Lucror Analytics

By Charles Macgregor

The Asia HY Trade Book for July 2023 includes a summary of our recommendations, as well as our high-conviction ideas. The report also features relative-value charts and lists of the bonds across Asia (ex-Japan) HY and crossover credits.


LianLian DigiTech IPO: The Bear Case

By Arun George

  • Lianlian DigiTech (2104619D CH), a digital payment services provider in China, has filed for an HKEx IPO to raise US$500 million, according to press reports.  
  • In LianLian DigiTech IPO: The Bull Case, we highlighted the key elements of the bull case. In this note, we outline the bear case.
  • The key elements of the bear case rest on margin pressure on the fastest-growing business, operating losses, an unconvincing path to profitability, FCF burn with a weak balance sheet.

💡 Before it’s here, it’s on Smartkarma

Sign Up for Free

The Smartkarma Preview Pass is your entry to the Independent Investment Research Network

  • ✓ Unlimited Research Summaries
  • ✓ Personalised Alerts
  • ✓ Custom Watchlists
  • ✓ Company Data and News
  • ✓ Events & Webinars